Cardiac myosin binding protein-C (cMyBP-C) is a trans-filament protein which, at its N'-region, connects thick and thin filaments to regulate cardiac contractility. The overall objective of the studies contained in this renewal of R01HL-105826 is to define the N'-region of cMyBP-C as a critical regulator of cardiac contractility. In particular, C0-C1f, which interacts only with actin, is generated by proteolysis of cMyBP-C during ischemia/reperfusion (I/R) injury and heart failure. On the other hand, C0-C2 interacts with both actin and myosin, connecting thin and thick filaments to regulate sarcomere function. On the basis of these findings, we will 1) use a novel transgenic mouse model expressing cMyBP-C (cMyBP-C110kDa) in which the C0-C1f region was ablated to study the necessity and sufficiency of this domain in regulating cardiac contractility and 2) use adeno-associated virus 9 (AAV9)-mediated expression of (i) recombinant C0-C2 to determine the sufficiency of N'-terminal C0-C2 in bundling thick and thin filaments in vivo and (ii) recombinant C0-C2?CTS, in which the calpain-targeted site (CTS) has been ablated, to determine its therapeutic potential in improving cardiac function pre- and post-I/R injury. The molecular mechanisms underlying the regulation of cMyBP-C and, in turn, its impact on sarcomere structure and function, are largely unknown. Our short-term goal is to elucidate the specific role(s) of the N'-region of cMyBP-C in the regulation of cardiac function, whereas our long-term goal is to determine the mechanisms by which cMyBP-C stabilizes sarcomeric structure and function, thereby conferring cardioprotection during I/R injury.
SPECIFIC AIM 1 will test the hypothesis that the C0-C1f domain of cMyBP-C, which is cleaved and released during I/R injury, is necessary for regulating cardiac function. Transgenic cMyBP-C110kDa mice will be used to determine the critical role of the N'-region of cMyBP-C at the sarcomere and whole-heart levels, compared to the control non-transgenic mice.
SPECIFIC AIM 2 will test the hypothesis that the C0-C2 domains of cMyBP-C are sufficient to bundle thick and thin filaments and to regulate normal cardiac function. AAV9-mediated expression of recombinant C0-C2 will be used to prevent or rescue contractile dysfunction in mouse models that lack either the N'-region (C0-C1f) or full-length cMyBP-C in vivo.
SPECIFIC AIM 3 will test the hypothesis that expression of recombinant C0-C2?CTS in vivo confers cardioprotection during I/R injury. Recombinant C0-C2?CTS protein is protected from calpain-mediated degradation. We expect AAV9-mediated expression of recombinant C0-C2?CTS to significantly reduce infarct size and apoptosis, as well as preserve contractile function during I/R injury. Together, these studies will determine the necessity and sufficiency of the N'-region (both C0-C1f and C0-C2) of cMyBP-C to regulate cardiac function, and, hence, provide therapy for myocardial injury and heart failure occurring during I/R injury.
The long-term objective is to understand the functional consequences of cardiac myosin binding protein-C on heart function. In particular, the proposed studies will determine the specific role(s) of the amino terminal-region of cardiac myosin binding protein-C in regulating sarcomere structure and function at the cardiac sarcomeric and whole-heart levels, leading to the development of potential cardioprotective therapeutic approaches to improve cardiac function in heart failure.
|McNamara, James W; Grimes, Kelly M; Sadayappan, Sakthivel (2018) Basic Cardiovascular Sciences Scientific Sessions 2018. Circ Res 123:1024-1029|
|McNamara, James W; Sadayappan, Sakthivel (2018) Skeletal myosin binding protein-C: An increasingly important regulator of striated muscle physiology. Arch Biochem Biophys 660:121-128|
|Sadayappan, Sakthivel (2018) My Life, My Heart, and My(osin) Binding Protein-C. Circ Res 122:918-920|
|Viswanathan, Shiv Kumar; Puckelwartz, Megan J; Mehta, Ashish et al. (2018) Association of Cardiomyopathy With MYBPC3 D389V and MYBPC3?25bpIntronic Deletion in South Asian Descendants. JAMA Cardiol 3:481-488|
|Lin, Brian Leei; Song, Taejeong; Sadayappan, Sakthivel (2017) Myofilaments: Movers and Rulers of the Sarcomere. Compr Physiol 7:675-692|
|Lynch 4th, Thomas L; Kuster, Diederik W D; Gonzalez, Beverly et al. (2017) Cardiac Myosin Binding Protein-C Autoantibodies are Potential Early Indicators of Cardiac Dysfunction and Patient Outcome in Acute Coronary Syndrome. JACC Basic Transl Sci 2:122-131|
|Lynch 4th, Thomas L; Ismahil, Mohamed Ameen; Jegga, Anil G et al. (2017) Cardiac inflammation in genetic dilated cardiomyopathy caused by MYBPC3 mutation. J Mol Cell Cardiol 102:83-93|
|Viswanathan, Shiv Kumar; Sanders, Heather K; McNamara, James W et al. (2017) Hypertrophic cardiomyopathy clinical phenotype is independent of gene mutation and mutation dosage. PLoS One 12:e0187948|
|Sadayappan, Sakthivel (2017) The Myofilament Field Revisited in the Age of Cellular and Molecular Biology. Circ Res 121:601-603|
|Sadayappan, Sakthivel (2017) Cardiovascular Early Careers: Past and Present. Circ Res 121:100-102|
Showing the most recent 10 out of 45 publications